{"name":"Almirall, S.A.","slug":"almirall-s-a","ticker":"","exchange":"","domain":"almirall.com","description":"Almirall, S.A. is a specialty pharmaceutical company focused on developing and commercializing treatments for dermatological conditions. The company has a diverse pipeline with several drugs in various stages of development, including marketed products and early-stage candidates.","hq":"Barcelona","founded":0,"employees":"N/A","ceo":"Gianfranco Nazzi","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"LAS106521","genericName":"LAS106521","slug":"las106521","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LAS41005","genericName":"LAS41005","slug":"las41005","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LASW1510","genericName":"LASW1510","slug":"lasw1510","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LAS41007","genericName":"LAS41007","slug":"las41007","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LAS41008","genericName":"LAS41008","slug":"las41008","indication":"Psoriasis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Experimental: LAS 41004 dosage 1","genericName":"Experimental: LAS 41004 dosage 1","slug":"experimental-las-41004-dosage-1","indication":"Other","status":"phase_2"},{"name":"LAD603","genericName":"LAD603","slug":"lad603","indication":"Other","status":"phase_2"},{"name":"LAS41003","genericName":"LAS41003","slug":"las41003","indication":"Other","status":"phase_2"},{"name":"Tirbanibulin ointment 1%","genericName":"Tirbanibulin ointment 1%","slug":"tirbanibulin-ointment-1","indication":"Other","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"KX2-391 Ointment 1%","genericName":"KX2-391 Ointment 1%","slug":"kx2-391-ointment-1","indication":"Atopic dermatitis","status":"phase_3"},{"name":"dapsone gel","genericName":"dapsone gel","slug":"dapsone-gel","indication":"Acne vulgaris","status":"marketed"},{"name":"dapsone gel vehicle","genericName":"dapsone gel vehicle","slug":"dapsone-gel-vehicle","indication":"Acne vulgaris (topical gel formulation)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"LASW1835","genericName":"LASW1835","slug":"lasw1835","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"vehicle of LAS41007","genericName":"vehicle of LAS41007","slug":"vehicle-of-las41007","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"}]}],"pipeline":[{"name":"Experimental: LAS 41004 dosage 1","genericName":"Experimental: LAS 41004 dosage 1","slug":"experimental-las-41004-dosage-1","phase":"phase_2","mechanism":"LAS 41004 is an investigational compound being developed by Almirall for dermatological or respiratory conditions, though its precise mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"LAS106521","genericName":"LAS106521","slug":"las106521","phase":"phase_3","mechanism":"LAS106521 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LAS41005","genericName":"LAS41005","slug":"las41005","phase":"phase_3","mechanism":"LAS41005 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LASW1510","genericName":"LASW1510","slug":"lasw1510","phase":"phase_3","mechanism":"LASW1510 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LASW1835","genericName":"LASW1835","slug":"lasw1835","phase":"phase_3","mechanism":"LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"KX2-391 Ointment 1%","genericName":"KX2-391 Ointment 1%","slug":"kx2-391-ointment-1","phase":"phase_3","mechanism":"KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis.","indications":["Atopic dermatitis"],"catalyst":""},{"name":"LAD603","genericName":"LAD603","slug":"lad603","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LAS41003","genericName":"LAS41003","slug":"las41003","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LAS41007","genericName":"LAS41007","slug":"las41007","phase":"phase_3","mechanism":"LAS41007 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LAS41008","genericName":"LAS41008","slug":"las41008","phase":"phase_3","mechanism":"LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Psoriasis","Atopic dermatitis"],"catalyst":""},{"name":"Tirbanibulin ointment 1%","genericName":"Tirbanibulin ointment 1%","slug":"tirbanibulin-ointment-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"dapsone gel","genericName":"dapsone gel","slug":"dapsone-gel","phase":"marketed","mechanism":"Small molecule","indications":["Acne vulgaris"],"catalyst":""},{"name":"dapsone gel vehicle","genericName":"dapsone gel vehicle","slug":"dapsone-gel-vehicle","phase":"phase_3","mechanism":"Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production.","indications":["Acne vulgaris (topical gel formulation)"],"catalyst":""},{"name":"vehicle of LAS41007","genericName":"vehicle of LAS41007","slug":"vehicle-of-las41007","phase":"phase_3","mechanism":"LAS41007 is a small molecule inhibitor of the PDE4 enzyme.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQeWdaTUdWamk4eXhCLU54VWJBVHRCUjZmd2hoMW1YTTJ0YV9GQl82d2IweTRWVnA0M0YwTjd1Nm5nRmV5Y3B5SFdjQTJ5RVZxWDBqdmYxMUFpS2pnRFBnN2FLSnU1RTE2WEJZejBGZW9WX1JtZVJNTDlvZzluNGc4NmJxUlIyV2FTRkVsUHpFSXM0NUp6REl1dE1nbTdxTEdNaWFsWEFCT1MxUlpSbGllaVN3LVdDMUc2TGdKZE5pS1g5NUpTM1kxRndUMDc3WlQ4dVo3aDE5TGZpQTNUN2JkOXpLQi1LdmJ4SC10aC1FVV9kdEtpQXd4cy13?oc=5","date":"2026-03-27","type":"deal","source":"TradingView","summary":"Zhejiang Huahai Pharmaceutical's Unit Signs Global Research And Licensing Deal With Almirall,S.A. - TradingView","headline":"Zhejiang Huahai Pharmaceutical's Unit Signs Global Research And Licensing Deal With Almirall,S.A.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOYWxFZUFjckVuM093OUwtd2hvR2ZVVmROTkpiR0dnOWxuTFZyV2JiQ2dDeXhxcjZSTmRPdzFraG50WXNzUWlvVzIzajg1SFpsc0hiYUhZUnhqUmxiRll6Y1lPSmk2WnF1Yjh2Z2RIZ2FZcHJBUVBoN2xiSHVsaUhiQkc3ejRpdTdnV3JQMDdJaG90NFVHbmQ5bU93c1Y5QWVRMzJ4VXdzdllQV1NoUktDZTk4cTdJUjVjSVFWdVFR?oc=5","date":"2026-03-25","type":"pipeline","source":"AD HOC NEWS","summary":"Almirall S.A. stock faces pressure amid pipeline delays and European pharma headwinds - AD HOC NEWS","headline":"Almirall S.A. stock faces pressure amid pipeline delays and European pharma headwinds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOVG95OFBFWXZmVldlSVFkMjNuOXlmX1pIOExvN0l3QjB4RWNfLVU4TmNpcGVVNlFuTEFXd2poa01OUjBoWDBFRUVHODVpNlFURmhIazdyMHNicnA2UXZ1T1Y5V2hOLUt0eHdJdzJGdUZ4TnVOZ0JyUmhJNjN1N2ZjZ01haVJWbFlFcUFMSGM3aEo1dFZobGFUUUZOOXAyVG9WdDlIdi1UQU9Yb2xaZ0VuOXhNRlh4eGVnYkZBM0NwbkJJQQ?oc=5","date":"2026-03-20","type":"pipeline","source":"AD HOC NEWS","summary":"Almirall S.A. stock faces pipeline pressure amid European pharma shifts - AD HOC NEWS","headline":"Almirall S.A. stock faces pipeline pressure amid European pharma shifts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxONGdLa1RpXzRPbDNkWmhPLVpfYnp0QU5kUEFjb3N4ZWpjM3YwUlZJUjJsc0dqekFsakEtZlpZYkZPaTcwUTFTdzZsc21uU0QyZXl1REJ0T3hHTXRrY2Z0OEpFM0FzdjdnMjBTTC1aQ2RZcXlNTUhEWGhCVTVPcG1jZ2pnRGp2cWJuNm1nUUhCQVZtdHpVeTlDWEJfQ29QVU1fUDFZcHgxWmtJRmlZcGQ0VW9fR0lZY0pxYXdjZXNmV1I?oc=5","date":"2026-03-13","type":"pipeline","source":"AD HOC NEWS","summary":"Almirall S.A. Stock (ISIN: ES0157097017) Faces Headwinds Amid Dermatology Pipeline Setbacks - AD HOC NEWS","headline":"Almirall S.A. Stock (ISIN: ES0157097017) Faces Headwinds Amid Dermatology Pipeline Setbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQb0haNGZnM1RDMGlTMjZHWlBzUlpjWWl6elV5TWtmMDhTa2owaVZRYTZFd1JkUHdQeVpJZ3JONXhHSGVFTWRHVnBMTXcyWVdNYzktVi11MVBEMVNxR0FrZWlfNXJsc2lrR0o1RlRFMU51SllHc2ZmczRVOHVtZmg3SVM4eXl4Y3JHd0UxRlB5SWJGYm5QaFAxNVBhS3ptblh5OGd3dE1sZWV4eENzQXVQUW9QQjBWcS03RGwzdm50cVBqYzBhMUpWRWozemcyM2tYUFJ3bzFsQnZvektFaHZpaC13Y3pHc0l5Q1F3RVBZNXl6Zw?oc=5","date":"2026-03-12","type":"deal","source":"Business Wire","summary":"Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships - Business Wire","headline":"Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT0l6NTBiSjVsUTh0N01aOEpsc1haX1h5MkZ6YmRKVHZoNnBmbG0yU1dtOURBRjJLOF85U3kydXBsTTFrYlVOS2NoZ3V0Q2NTSUJEVTFlcHpiSEt4OHFjUEpucjMyQ28tbFhPQTIxZllmczAweTVESU5UR1VXYmFYTjlJNXNPczJtSVNUUHZkcnAyZ2N4Z2QxSk9zVm96UmUtRENWVDJXeVRNMnRHazNXWFpaS085bnRiRk5iVUFwMU1YSlJnU3ppcw?oc=5","date":"2026-02-27","type":"pipeline","source":"AD HOC NEWS","summary":"Almirall Stock: Quiet European Pharma That US Investors Are Starting To Notice - AD HOC NEWS","headline":"Almirall Stock: Quiet European Pharma That US Investors Are Starting To Notice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxQTDNQTTFmRTl3V0FUZWJBOUp4bXlkZGtSZUF0TGpNTXZxSFRuaHR3aDM0eFFJdUZuOGJfaVl4T2w5V0RqRGE5MXFVeHJoc3FZTGJiZjJ4YnFzVWRiMWdpSXhHTHlSWHE0SHFQcml6dTQ3RzE1dnl1Yk1LV1pHTm1wbVNmbHpvMHdZbF85TGZJZXVjWXhsNnQ2NEtVSXJNZ0ZSTkI0OUxBQXdZUFd0TWJxVWdLQXJYT2ZuZER1cEJhNU9tZU9OaHh3RkltZl82NU9RazQ1Y3BUaU5XNF85bm4xd2tPZnhFMXdUQ1R1NncwZ09PVUhlT1VyLXZUeW4wZHV4aEx6d0lzb181Ymt1aURwOHNwUEE2NHh3U1FVcDlsRjNRYmpEZTRr?oc=5","date":"2026-01-14","type":"pipeline","source":"Business Wire","summary":"Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference - Business Wire","headline":"Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morg","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-13","type":"earnings","source":"simplywall.st","summary":"Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - simplywall.st","headline":"Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9rTkRjaF9iN0VOem16T3VMbFpUN1NRc3d6azhyaEdqX3ZmY0hwX01pa1JnR0RkV0tOUkVyRU96UURORU94VXAzNTB3aWtJclJsUlFjMjRvcmRCeExTU3NDTEFrcWJDYld5Z2k4bjM0dEE3UQ?oc=5","date":"2025-05-12","type":"earnings","source":"BioSpace","summary":"Almirall Q1 2025 Results - BioSpace","headline":"Almirall Q1 2025 Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxQcUdTOWNWTzBpTE45YUxxZldlajd4UUFxcHRCR0RSSmE4LXRtVEdSQ3VzOV9MX0lTQ1Y2ejRuNG9rcDZVQnFSU0EwclZUNEM1YmNoNVA2RUQwTkZQTTdXRmdiRjBic0pmcnBGWHBSNFdsTGl1Zm5FazRPZGg5aFJteFdKVHFlbUM5OVZSVHlQTzdvSHhkbmtSaGRGcTFVb3Jnc1ZLdVY5Ql9zTi1HcDQxdUxQUjFkTEtqQ1FzbjM1cmxfMTBHY250QklMWmJtZnJuVWdqMjlxQ2thcnFVS3lRaUpjVURsYm1GTzlaVEtla3RFdkRDTkRsYVktdDkxTWFNLU1kTFo3bEdXNFlpTXlnNGRzLTRfUllybHlpRE9BVm56ZmJqaEE?oc=5","date":"2025-02-24","type":"pipeline","source":"BioSpace","summary":"Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline - BioSpace","headline":"Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNQkFQbVJORnV2Wld2SG1wdkdOWUFvTWQyZkJXaUd6WGVqbGdnWms3cjNsOF9HckpYMl9BT0huaXhCRWw1OXF4NjZKdEt2WXV1a3lCdDRpY1NrSDZSOU02and0cDVnUlNJQ1J6b1FSNDdpb290NHVUeS1jYWVIc2tCcHVDcXpaay1rbnlCVkt2RDllVGdjMEtfclJha0QtRFplQXBlekQ4MUFkZDVpRjd5a0dTb1NmZ0hnT3RVOTdTelNjeHBmRmFtX3RlUm9QQnN2cFEtUGZUN1FVLVVp?oc=5","date":"2024-10-15","type":"regulatory","source":"BioSpace","summary":"Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe - BioSpace","headline":"Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPaFRKZFZUeEdTb19vb0o3cVpTb1FGNmU3QlNOMnJPNkhISVZsVzdJYWdaSGNaX21mV2o3eTVwVjJqOG9kYnctYWRjX05PcHFkREdOZnlFWF9uVm4ySUJMS1F6ZGR5elV3dUpoY2pKUUtaZWpKMUVWUzY2SUhsNTlnc3EwVlBNWXFNZWI3VHB6bVpWbVhFNGdYdV9jakJRNTVrdFlfNE5wQQ?oc=5","date":"2023-10-10","type":"pipeline","source":"Contract Pharma","summary":"Centrient Pharma, Almirall Open Innovation Hub in Barcelona - Contract Pharma","headline":"Centrient Pharma, Almirall Open Innovation Hub in Barcelona","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_2":3,"phase_3":9,"marketed":2},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}